Found: 34
Select item for more details and to access through your institution.
A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 879, doi. 10.1007/s40273-015-0278-7
- By:
- Publication type:
- Article
The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 3, p. 229, doi. 10.1007/s40273-012-0022-5
- By:
- Publication type:
- Article
Genetic Testing in Combination with Preventive Donepezil Treatment for Patients with Amnestic Mild Cognitive Impairment.
- Published in:
- Molecular Diagnosis & Therapy, 2012, v. 16, n. 6, p. 389, doi. 10.1007/s40291-012-0010-7
- By:
- Publication type:
- Article
Impact of rarity on Canadian oncology health technology assessment and funding.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces.
- Published in:
- MDM Policy & Practice, 2021, v. 6, n. 1, p. 1, doi. 10.1177/23814683211021060
- By:
- Publication type:
- Article
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
- Published in:
- Current Oncology, 2024, v. 31, n. 4, p. 1876, doi. 10.3390/curroncol31040141
- By:
- Publication type:
- Article
Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
- Published in:
- Current Oncology, 2023, v. 30, n. 4, p. 3776, doi. 10.3390/curroncol30040286
- By:
- Publication type:
- Article
Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
- Published in:
- Current Oncology, 2022, v. 29, n. 3, p. 2046, doi. 10.3390/curroncol29030165
- By:
- Publication type:
- Article
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
- Published in:
- Current Oncology, 2021, v. 28, n. 6, p. 4645, doi. 10.3390/curroncol28060392
- By:
- Publication type:
- Article
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group.
- Published in:
- Current Oncology, 2021, v. 28, n. 5, p. 4174, doi. 10.3390/curroncol28050354
- By:
- Publication type:
- Article
Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Improving chronic disease prevention and screening in primary care: results of the BETTER pragmatic cluster randomized controlled trial.
- Published in:
- BMC Family Practice, 2013, v. 14, n. 1, p. 175, doi. 10.1186/1471-2296-14-175
- By:
- Publication type:
- Article
Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer.
- Published in:
- Canadian Urological Association Journal, 2019, v. 13, n. 12, p. 396, doi. 10.5489/cuaj.5889
- By:
- Publication type:
- Article
The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 19, p. 7072, doi. 10.1002/cam4.3362
- By:
- Publication type:
- Article
Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 1, p. 160, doi. 10.1002/cam4.2705
- By:
- Publication type:
- Article
Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer?
- Published in:
- Cancer Medicine, 2020, v. 9, n. 1, p. 215, doi. 10.1002/cam4.2704
- By:
- Publication type:
- Article
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Introduction to Cost-Effectiveness Analysis for Clinicians.
- Published in:
- University of Toronto Medical Journal, 2013, v. 90, n. 3, p. 103
- By:
- Publication type:
- Article
Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
- Published in:
- BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08746-z
- By:
- Publication type:
- Article
Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
- Published in:
- BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08746-z
- By:
- Publication type:
- Article
Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 10, p. 11451, doi. 10.1002/cam4.5862
- By:
- Publication type:
- Article
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.
- Published in:
- BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-586
- By:
- Publication type:
- Article
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
- Published in:
- JNCI Cancer Spectrum, 2022, v. 6, n. 4, p. 1, doi. 10.1093/jncics/pkac047
- By:
- Publication type:
- Article
Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
- Published in:
- CMAJ Open, 2020, v. 8, n. 4, p. E772, doi. 10.9778/cmajo.20200118
- By:
- Publication type:
- Article
Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 3, p. e2145460, doi. 10.1001/jamanetworkopen.2021.45460
- By:
- Publication type:
- Article
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 11, p. e2133388, doi. 10.1001/jamanetworkopen.2021.33388
- By:
- Publication type:
- Article
Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada.
- Published in:
- International Journal of Cancer, 2021, v. 148, n. 8, p. 1910, doi. 10.1002/ijc.33357
- By:
- Publication type:
- Article
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 8, p. e2225118, doi. 10.1001/jamanetworkopen.2022.25118
- By:
- Publication type:
- Article
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 8, p. 1, doi. 10.1001/jamanetworkopen.2022.25118
- By:
- Publication type:
- Article